Highlights

  • dorsaVi secured commitments for a Placement to raise A$3.0 million before costs.
  • The company plans to direct proceeds toward movement-data capabilities, robotics-related data applications and RRAM development.
  • The placement involves 136,363,636 new ordinary shares at A$0.022 each, together with attached unlisted options.
  • Settlement is expected on 19 October 2026, subject to the announced placement timetable.
  • The first RRAM-CMOS validation chip has completed front-end and middle-of-line fabrication and is moving into RRAM integration.

dorsaVi Limited (ASX:DVL) develops wearable sensors, software and movement-analysis technologies designed to measure human movement and muscle activity, while also advancing RRAM semiconductor technology. On 6 October 2026, the company announced a A$3.0 million placement intended to fund its human-movement data strategy, semiconductor development programme and general working-capital requirements.

Placement Structure and Timing

dorsaVi said it had received commitments to raise A$3.0 million before costs through the issue of 136,363,636 fully paid ordinary shares at A$0.022 each. Participants are also expected to receive one unlisted option for every two shares subscribed, resulting in 68,181,818 options. Each option has an exercise price of A$0.045 and is due to expire three years from issue.

The company stated that 13,363,636 shares will be issued under its ASX Listing Rule 7.1 capacity and 123,300,000 shares under its additional Listing Rule 7.1A capacity. The attached Options are also expected to be issued under Listing Rule 7.1. Settlement is scheduled for 19 October 2026.

How dorsaVi Plans to Use the Funds

The planned use of proceeds spans two main technology areas. dorsaVi intends to expand its clinical-grade human-movement data library and strengthen its bespoke data-capture capability using wearable sensors and video artificial intelligence. The company said these capabilities are intended to support data requirements associated with humanoid robotics development and other physical-AI applications.

Funding is also allocated to the company’s neuromorphic intellectual property and resistive random-access memory, or RRAM, programme. Remaining proceeds are intended for partner evaluations, working Capital and offer costs.

RRAM Validation Chip Progress

dorsaVi reported that its first RRAM-CMOS validation chip has completed front-end and middle-of-line fabrication. The wafers are now expected to move into the proprietary RRAM integration stage. The announcement did not provide a completion date for that stage, so the next technical milestone will depend on progress through the integration process.

Capital Raising Context

The placement is a financing transaction rather than operating revenue. The company did not announce commercial contracts tied to the robotics or defence-related applications referenced in its funding plan. Accordingly, the immediate effect of the transaction is to provide additional capital for development activities rather than to establish revenue from those emerging applications.

Key Insights

The A$3.0 million placement gives dorsaVi additional funding for its movement-data capabilities and semiconductor programme at a time when the company is broadening its technology focus. Near-term attention is likely to centre on completion of the placement and progression of the validation-chip wafers into RRAM integration. The commercial significance of the broader robotics and physical-AI strategy will depend on future development milestones and customer or partner activity disclosed by the company.